Gilaberte Reyzabal Sergio, Isenberg David
Internal Medicine Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom.
Front Med (Lausanne). 2022 May 16;9:882891. doi: 10.3389/fmed.2022.882891. eCollection 2022.
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.
已明确利妥昔单抗治疗对B细胞恶性肿瘤和自身免疫性风湿性疾病均有用。然而，这种治疗与过敏反应风险增加相关。我们回顾了这些反应在不同情况下发生的频率。当利妥昔单抗用于治疗类风湿关节炎和系统性红斑狼疮时，这些反应似乎较少见，这可能是因为这些患者在使用利妥昔单抗时总是同时使用类固醇，而在治疗B细胞恶性肿瘤时不一定如此。
